Literature DB >> 7546836

TP53 abnormalities and genetic instability in breast cancer.

J E Eyfjörd1, S Thorlacius, R Valgardsdottir, S Gretarsdottir, M Steinarsdottir, K Anamthawat-Jonsson.   

Abstract

TP53 abnormalities in breast carcinomas and inherited TP53 changes in breast cancer patients and in Li-Fraumeni-like families were looked for. Tumours were screened for mutations in the TP53 gene by means of the PCR-CDGE method followed by PCR and direct sequencing. Allelic loss was determined by polymorphic markers, by comparing normal and tumour DNA. Abnormal protein expression was examined by immunohistochemical staining. TP53 abnormalities in the tumours were examined in relation to genetic instability, clinical data and family history. Genetic instability was studied by detection of oncogene amplification, allelic loss, karyotype analysis and fluorescent in situ hybridization, FISH. Our studies showed that TP53 abnormalities were significantly associated with amplification of the erbB2 oncogene and allelic loss on chromosome 17. Chromosomal abnormalities were also significantly more common in tumours with TP53 abnormalities. Looking at clinical data we found significant association between TP53 abnormalities and poor prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 7546836     DOI: 10.3109/02841869509094045

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

1.  p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Authors:  Ellen J Schlette; Joan Admirand; William Wierda; Lynne Abruzzo; Katherine I Lin; Susan O'Brien; Susan Lerner; Michael J Keating; Constantine Tam
Journal:  Leuk Lymphoma       Date:  2009-10

2.  Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.

Authors:  Adam Shlien; Uri Tabori; Christian R Marshall; Malgorzata Pienkowska; Lars Feuk; Ana Novokmet; Sonia Nanda; Harriet Druker; Stephen W Scherer; David Malkin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-06       Impact factor: 11.205

3.  Saliva samples as a source of DNA for high throughput genotyping: an acceptable and sufficient means in improvement of risk estimation throughout mammographic diagnostics.

Authors:  U G Poehls; C C Hack; A B Ekici; M W Beckmann; P A Fasching; M Ruebner; H Huebner
Journal:  Eur J Med Res       Date:  2018-04-27       Impact factor: 2.175

4.  Defining Signatures of Arm-Wise Copy Number Change and Their Associated Drivers in Kidney Cancers.

Authors:  Graeme Benstead-Hume; Sarah K Wooller; Jessica A Downs; Frances M G Pearl
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.